Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Autolus Therapeutics (AUTL) Tax Provisions (2017 - 2025)

Autolus Therapeutics (AUTL) has disclosed Tax Provisions for 6 consecutive years, with $533000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Tax Provisions rose 2322.73% year-over-year to $533000.0, compared with a TTM value of $4.6 million through Sep 2025, up 11160.98%, and an annual FY2024 reading of $1.5 million, up 8142.11% over the prior year.
  • Tax Provisions was $533000.0 for Q3 2025 at Autolus Therapeutics, up from $397000.0 in the prior quarter.
  • Across five years, Tax Provisions topped out at $19.6 million in Q4 2022 and bottomed at -$26000.0 in Q1 2022.
  • Average Tax Provisions over 4 years is $1.9 million, with a median of $40000.0 recorded in 2023.
  • The sharpest move saw Tax Provisions tumbled 100.12% in 2023, then soared 27912.5% in 2025.
  • Year by year, Tax Provisions stood at $19.6 million in 2022, then crashed by 100.12% to -$24000.0 in 2023, then skyrocketed by 6191.67% to $1.5 million in 2024, then tumbled by 63.54% to $533000.0 in 2025.
  • Business Quant data shows Tax Provisions for AUTL at $533000.0 in Q3 2025, $397000.0 in Q2 2025, and $2.2 million in Q1 2025.